OTC · CIK 0001445815
BIXT BIOXYTRAN, INC
Insider trading from SEC Form 4. Last filing Nov 18, 2025. Close $0.02 on Oct 9, 2026, +14% from the 52-week low and -75% from the high.
In brief
BIOXYTRAN, INC (BIXT) has 18 SEC Form 4 filings on file from 7 insiders, the latest filed on Nov 18, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at BIXT. The newest: Alan M Hoberman (director) bought $126k of stock on Nov 18, 2025, filed Nov 18, 2025, scored 34 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at BIOXYTRAN, INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 34Weak | Alan M Hoberman director buy | $126k 210,000 shares | - | - |
Transactions
Every row filed, 28 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 14, 2025 | Anders Utter director | AGrant or award preferred | +38,588 | $0.35 | $14k | 372,580 | Nov 18, 2025 |
| Oct 24, 2024 | David Platt CEO | JOther preferredindirect: through NDPD Pharma | -14,085,410 | $0.29 | $4.0M | 0 | Nov 18, 2025 |
| Oct 25, 2024 | Ola Soderquist CFO | JOther preferred | +10,069,396 | $0.55 | $5.5M | 13,976,456 | Nov 18, 2025 |
| Aug 12, 2025 | Dale H Conaway director | AGrant or award preferred | +10,417 | $0.49 | $5,052 | 340,589 | Nov 18, 2025 |
| Aug 12, 2025 | Radka Milanova director | AGrant or award preferred | +10,417 | $0.49 | $5,052 | 165,100 | Nov 18, 2025 |
| Aug 12, 2025 | Alan M Hoberman director | AGrant or award preferred | +10,417 | $0.49 | $5,052 | 377,619 | Nov 18, 2025 |
| Oct 25, 2024 | Michael Sheikh CCO | JOther preferred | +6,614,720 | $0.55 | $3.6M | 8,214,720 | Nov 18, 2025 |
| Oct 24, 2024 | David Platt CEO | JOther preferred | +11,433,448 | $0.55 | $6.2M | 20,038,903 | Nov 18, 2025 |
| Oct 25, 2024 | Ola Soderquist CFO | JOther preferred | +100,000 | $0.01 | $500 | 13,876,456 | Nov 18, 2025 |
| Nov 14, 2025 | Dale H Conaway director | AGrant or award preferred | +38,588 | $0.35 | $14k | 379,177 | Nov 18, 2025 |
| Nov 14, 2025 | Radka Milanova director | AGrant or award preferred | +38,588 | $0.35 | $14k | 203,688 | Nov 18, 2025 |
| Nov 14, 2025 | Alan M Hoberman director | AGrant or award preferred | +38,588 | $0.35 | $14k | 416,207 | Nov 18, 2025 |
| Nov 18, 2025 | Alan M Hoberman director | POpen-market purchase common | +210,000 | $0.60 | $126k | 210,000 | Nov 18, 2025 |
| Oct 25, 2024 | Ola Soderquist CFO | JOther common | +500,000 | $0.00 | $500 | 500,000 | Nov 18, 2025 |
| Jan 6, 2025 | Dale H Conaway director | AGrant or award Preferred | +97,535 | $0.32 | $31k | 330,172 | Jan 14, 2025 |
| Jan 6, 2025 | Anders Utter director | AGrant or award preferred | +97,535 | $0.32 | $31k | 333,992 | Jan 14, 2025 |
| Jan 6, 2025 | Radka Milanova director | AGrant or award Preferred | +97,535 | $0.32 | $31k | 154,683 | Jan 14, 2025 |
| Jan 6, 2025 | Alan M Hoberman director | AGrant or award Preferred | +97,535 | $0.32 | $31k | 367,202 | Jan 14, 2025 |
| Oct 25, 2024 | Dale H Conaway director | AGrant or award preferred | +20,619 | $0.46 | $9,485 | 232,637 | Oct 28, 2024 |
| Oct 25, 2024 | Anders Utter director | AGrant or award preferred | +20,619 | $0.46 | $9,485 | 236,457 | Oct 28, 2024 |
| Oct 25, 2024 | David Platt CEO | JOther Preferredindirect: through NDPD Pharma | -14,085,410 | $0.29 | $4.0M | 0 | Oct 28, 2024 |
| Oct 25, 2024 | Radka Milanova director | AGrant or award preferred | +20,619 | $0.46 | $9,485 | 57,148 | Oct 28, 2024 |
| Oct 25, 2024 | Ola Soderquist CFO | JOther preferred | +10,197,611 | $0.55 | $5.6M | 14,104,671 | Oct 28, 2024 |
| Oct 25, 2024 | Alan M Hoberman director | AGrant or award preferred | +20,619 | $0.46 | $9,485 | 269,667 | Oct 28, 2024 |
| Oct 24, 2024 | Michael Sheikh Chief Communications Officer | JOther Preferred | +6,473,921 | $0.55 | $3.5M | 8,073,921 | Oct 28, 2024 |
| Oct 25, 2024 | David Platt CEO | JOther Preferred | +11,190,077 | $0.55 | $6.1M | 19,795,532 | Oct 28, 2024 |
| Oct 25, 2024 | Ola Soderquist CFO | JOther preferred | -100,000 | $0.01 | $500 | 14,004,671 | Oct 28, 2024 |
| Oct 25, 2024 | Ola Soderquist CFO | JOther common | +500,000 | $0.00 | $500 | 500,000 | Oct 28, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Dale H Conawaydirector
- Alan M Hobermandirector
- Radka Milanovadirector
- David PlattCEO
- Michael SheikhCCO
- Ola SoderquistCFO
- Anders Utterdirector
Questions about BIXT
Answered from the filings on this page, as of the latest one.
Are insiders buying BIXT?
No. In the last 90 days no insider at BIOXYTRAN, INC bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade BIXT on the open market?
Alan M Hoberman (director) bought $126k of BIXT on Nov 18, 2025 and filed the Form 4 on Nov 18, 2025. InsiderTell scored 34 (weak).
How many insiders file Form 4 at BIOXYTRAN, INC?
7 people have filed a Form 4 at BIOXYTRAN, INC, among them Dale H Conaway (director), Alan M Hoberman (director), Radka Milanova (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.